Setmelanotide Cuts BMI, Hunger in Phase 3 Trial for Hypothalamic Obesity

Setmelanotide (Imcivree; Rhythm Pharmaceuticals) produced significantly greater reductions in body mass index (BMI) and hunger than placebo in the largest and longest placebo-controlled trial ever conducted in acquired hypothalamic obesity, according to results of the phase 3 TRANSCEND trial (NCT05774756) published in the New England Journal of Medicine.¹

Acquired hypothalamic obesity is a rare condition marked by rapid, sustained weight gain following injury to the hypothalamus, most often from craniopharyngioma or its treatment. No approved therapies have directly targeted the underlying melanocortin-4 receptor (MC4R) pathway dysfunction thought to drive the disease until now.

“Patients with acquired hypothalamic obesity and their families face an urgent need for effective treatment options,” senior study author Christian Roth, a pediatric endocrinologist and principal investigator of the Norcliffe Foundation Center for Integrative Brain Research at Seattle Children’s Research Institute, said in a statement.² “The results of the TRANSCEND trial demonstrate meaningful and consistent reductions in body mass index as well as improvements in hunger. For patients and families who experience the accelerated and sustained weight gain associated with hypothalamic injury, these findings represent a potentially transformative therapeutic advancement.”

How Was the Trial Designed?

Researchers enrolled 120 participants aged 4 to 66 years across 29 sites in 6 countries and randomly assigned them 2:1 to receive subcutaneous setmelanotide (1.5 to 3.0 mg daily) or placebo for 52 weeks following a dose-escalation period.¹ Eligible participants had a BMI at or above the 95th percentile for age and sex (if younger than 18 years) or a BMI of at least 30 (if 18 years or older), along with a documented history of hypothalamic tumor, lesion, or injury. Craniopharyngioma was the most common underlying cause, accounting for 78% of cases. The primary end point was mean percent change in BMI from baseline to week 52.

What Were the Key Efficacy Findings?

Setmelanotide produced a least-squares mean BMI change of −16.5% compared with +3.3% with placebo, a treatment difference of −19.8 percentage points (P < .001). A BMI reduction of at least 5%, or a BMI z-score reduction of at least 0.2 points in participants younger than 18 years, occurred in 83% of the setmelanotide group compared with 21% of the placebo group (P < .001).

Hunger scores, assessed using an 11-point scale among participants 12 years and older, decreased by −2.73 points with setmelanotide vs −1.45 with placebo (P = .009). Investigators also reported favorable changes in waist circumference, cholesterol, glycated hemoglobin, and liver enzymes, along with quality-of-life gains.

What Safety Signals Emerged?

Adverse events occurred in 100% of participants receiving setmelanotide and 90% of those receiving placebo; serious adverse events occurred in 28% and 8%, respectively. The most common adverse events with setmelanotide were skin hyperpigmentation (56%), nausea (51%), vomiting (40%), and headache (38%).

A higher rate of melanocytic nevi was also observed in the treatment group. Three participants with pre-existing secondary adrenal insufficiency had serious adverse events related to that condition, and 1 participant experienced treatment-related hypernatremia linked to vomiting-related interruption of desmopressin use; all were managed clinically. One death from a seizure in a participant with a pre-existing seizure disorder was considered unrelated to treatment.

The authors noted that because more than 80% of participants were receiving desmopressin for arginine vasopressin deficiency, reduced hunger-driven food and fluid intake may have compounded fluid and electrolyte risks in this population, underscoring the need for close monitoring during therapy.

How Does This Fit Into the Broader Treatment Landscape?

The findings build on earlier phase 2 and real-world data suggesting that restoring α-melanocyte-stimulating hormone signaling through melanocortin-4 receptor agonism can meaningfully offset the hyperphagia and impaired energy expenditure characteristic of acquired hypothalamic obesity.

The FDA approved setmelanotide for acquired hypothalamic obesity in patients 4 years and older in March 2026, with the European Medicines Agency's Committee for Medicinal Products for Human Use recommending a similar authorization the same month.² A regulatory submission is also under review in Japan. Study authors noted that the 52-week trial duration is a limitation given that hypothalamic injury—and the obesity it drives—is permanent; a long-term extension trial is ongoing to evaluate outcomes beyond 1 year.¹

References

1. Miller JL, van Santen HM, Phillips SA, et al. Setmelanotide for the treatment of acquired hypothalamic obesity. N Engl J Med. 2026;395(2):138-150. doi:10.1056/NEJMoa2512275
2. Rhythm Pharmaceuticals announces The New England Journal of Medicine publication of phase 3 TRANSCEND trial results in acquired hypothalamic obesity. News release. Rhythm Pharmaceuticals, Inc. July 8, 2026. Accessed July 10, 2026. https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-new-england-journal-medicine